AI Article Synopsis
- The study aimed to assess the effectiveness and safety of low-dose interferon alpha-2a (IFNα2a) in patients with Behçet's syndrome (BS) who had resistance to other treatments for vascular or neurological issues.
- A total of 25 BS patients were treated with IFNα2a and showed significant clinical improvement after a median follow-up of 23 months, with notable reductions in disease activity scores and inflammation markers.
- The findings suggest that low-dose IFNα2a, in conjunction with existing therapies, is safe and effective for managing refractory BS without causing serious adverse events.
Article Abstract
Objective: The aim of this study was to evaluate the effectiveness and safety of low-dose interferon alpha-2a (IFNα2a) in Behçet's syndrome (BS) patients with refractory vascular/cardiac or neurological involvement.
Methods: In this retrospective cohort study, we consecutively included 25 BS patients with refractory vascular/cardiac ( = 16) or neurological involvement ( = 9) who received IFNα2a treatment in our center between June 2018 and September 2021. The low-dose IFNα2a (3 million IU, every other day) was used as an add-on treatment with the continuation of glucocorticoids (GCs) and immunosuppressants.
Results: In total, 25 patients (20 males, 5 females) with a mean age of 31.92 ± 9.25 years were included. IFNα2a was administered for BS patients with refractory vascular/cardiac involvement ( = 16) and neurological involvement ( = 9). Before the initiation of IFNα2a, patients had insufficient response or intolerance to conventional therapies. After a median follow-up of 23 [interquartile range (IQR), 11-30] months, all patients achieved clinical improvement. The Behçet's disease Current Activity Form (BDCAF) score improved significantly (5 0, median, < 0.0001). BS Overall Damage Index (BODI) and vasculitis damage index (VDI) remain stable ( > 0.05). Decrease in erythrocyte sedimentation rate [ESR; 24 (IQR, 12-43.5) 5 (IQR, 2.75-10.5) mm/h, = 0.0001] and C-reactive protein [CRP; 6.64 (IQR, 3.67-19.82) 1.24 (IQR, 0.24-3.12) mg/liter, < 0.005] was achieved effectively. The median GCs dosage tapered from 26.25 (IQR, 11.88-41.25) to 10.00 (IQR, 7.50-10.63) mg/d, < 0.0001. Immunosuppressants were also reduced in number ( < 0.005). No serious adverse events were observed during follow-up.
Conclusion: Our study suggests that low-dose IFNα2a, combined with GCs and immunosuppressants, is well-tolerated and effective for BS patients with refractory vascular/cardiac or neurological involvement and has a steroid- and immunosuppressant-sparing effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340357 | PMC |
| http://dx.doi.org/10.1177/20406223221111285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease.
Heliyon
December 2024
Medicinal Chemistry Department, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Alzheimer's disease (AD), a chronic neurodegenerative disease, is clinically characterized by loss of memory and learning ability among other neurological deficits. Amyloid plaques, hyperphosphorylated tau protein, and neurofibrillary tangles involve in AD etiology. Meanwhile, enzymes and their inhibitors have become the focus of research in AD treatment.
View Article and Find Full Text PDFSalmonella infections are widely known to cause gastroenteritis, especially in areas of poor hygiene and sanitation. Common symptoms include sustained fever, chills, and abdominal pain. Sepsis, disseminated intravascular coagulation (DIC), various neurological manifestations, and multiorgan failure are other uncommon presentations.
View Article and Find Full Text PDFA Rare Case of Polymicrogyria in an Elderly Individual With Unique Polygenic Underlining.
Cureus
November 2024
Department of Surgery - Center for Anatomical Science and Education, Saint Louis University School of Medicine, St. Louis, USA.
Polymicrogyria (PMG) is the most common malformation of cortical development (MCD) and presents as an irregularly patterned cortical surface with numerous small gyri and shallow sulci leading to various neurological deficits including developmental delays, intellectual disability, epilepsy, and language and motor issues. The presentation of PMG varies and is often found in conjunction with other congenital anomalies. Histologically, PMG features an abnormal cortical structure and dyslamination, resulting in its classification as a defect of neuronal migration and organization.
View Article and Find Full Text PDFConcomitant Amyotrophic Lateral Sclerosis and Rheumatoid Arthritis: A Case Report.
Cureus
November 2024
Internal Medicine/Rheumatology, Ibn Sina University for Medical and Pharmaceutical Sciences, Baghdad, IRQ.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative motor neuron disease that leads to a gradual loss of motor neurons manifesting as progressive weakness, dysarthria, and respiratory decline, with a relatively short life expectancy. Rheumatoid arthritis (RA) is an autoimmune disorder characterized by polyarthritis and affects multiple systems. Motor neuron involvement is rare in rheumatoid arthritis.
View Article and Find Full Text PDFAnti-N-methyl-D-aspartate (NMDA) receptor encephalitis is a rare autoimmune disorder that typically presents with neuropsychiatric symptoms and medial temporal lobe involvement. We report the case of a 24-year-old female with no significant medical history, who developed severe anxiety, memory deficits, and confusion over a two-week period. Neurological examination revealed cognitive dysfunction, asymmetric limb movements, and psychosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!